Brand-name vs compounded
Hers vs MedVi: Brand-Name or Compounded? (2026)
Hers costs $1,788 a year against $3,468 for MedVi. Full 2026 comparison of price, medication class and included support.
Published · Pricing as published in our provider dataset, synced · Editorial scores 9.8 and 9.2 out of 10
We may receive compensation when you click partner links. Rankings are based on research methodology, not sponsorship.
MedVi and Hers both promise a fast route to GLP-1 treatment without an office visit. What they promise afterward is where they separate.
The dividing line is regulatory, not cosmetic: Hers works with product the FDA has reviewed and approved, while MedVi runs on compounded medication prepared by a pharmacy rather than manufactured under an approved application. Everything else about the two — price, support, shipping — follows from that decision.
Each program is read on its own published terms first, then against the other on the four things that decide satisfaction: price, predictability, formulary and access to a clinician. Every figure traces back to the provider's own published material, and the missing ones stay missing.
The short answer
- Lowest 12-month cost
- Hers — $1,788 against $2,592 at MedVi, on each provider's own best published pricing.
- FDA-approved medication
- Hers — FDA-approved Wegovy pill (oral semaglutide) and Wegovy injectable pen — a finished product the FDA has reviewed, rather than a compounded preparation.
- Fastest route to a first shipment
- Hers — Online intake with clinician review, then home delivery, no insurance required.
- Widest medication choice
- Hers — FDA-approved Wegovy pill (oral semaglutide) and Wegovy injectable pen.
Hers and MedVi, side by side
Scan the pricing rows first, then the medication row. Those two settle most of these decisions between them.
| Hers | MedVi | |
|---|---|---|
| Advertised price | Wegovy pill from $149/mo, injectable from $199/mo | $179 promotional first month |
| Rate after promotions | $149/mo | $299/mo |
| Pricing structure | Published rate per medication | Promotional first month, then standard rate |
| Medication | FDA-approved Wegovy pill (oral semaglutide) and Wegovy injectable pen | Compounded semaglutide |
| Support model | Provider check-ins included | No coaching program stated |
| Shipping | Home delivery, no insurance required | Fast, free shipping |
| Price transparency | Published upfront | Published upfront |
| Tirzepatide | Not published | Not published |
| Patient reviews | 6,200 | 12,896 |
| eRxDoctor score | 9.8/10 | 9.2/10 |
The real cost: six months and twelve
Both providers lead with a number designed to get you through the intake. The figures underneath convert both offers into what you will have spent by month six and month twelve.
| Hers | MedVi | |
|---|---|---|
| First month | $149 | $179 |
| Months 2 onward | $149/mo | $299/mo |
| 6-month total | $894 | $1,674 |
| 12-month total | $1,788 | $3,468 |
| Best published plan | No multi-month discount published | 3-month plan at $649 — $2,592/yr |
Hers finishes the year $804 cheaper. For some patients the support MedVi bundles closes that gap; for a patient who only needs the prescription written, it does not.
Price escalation to plan for: MedVi moves from $179 to $299, a 67% increase. Set a calendar reminder for the month it changes.
Approved medication or compounded preparation
Hers dispenses FDA-approved Wegovy pill (oral semaglutide) and Wegovy injectable pen: an approved finished drug, meaning the agency has reviewed both the evidence behind it and the facility that makes it.
Across from that, MedVi offers compounded semaglutide — prepared by a pharmacy rather than manufactured under approval. The price advantage and the reduced oversight are the same fact seen from two sides.
This is the decision to make deliberately rather than by price. If the regulatory status of what you are injecting weekly matters to you, that settles it toward Hers; if cost is the barrier that has kept you from treating at all, MedVi exists for a reason.
Hers: what you are buying
The pitch is brand-name Wegovy at a price that usually buys compounded medication elsewhere. Hers offers FDA-approved Wegovy® (brand-name semaglutide) with a personalized care team and ongoing dose check-ins, no compounded medications.
You start with online intake with clinician review; medication arrives via home delivery, no insurance required. The price behaves as published rate per medication.
Personalized care team with ongoing dose check-ins. The formulary covers FDA-approved Wegovy pill (oral semaglutide) and Wegovy injectable pen.
Hers pros
- No insurance required
- FDA-approved brand-name Wegovy®, not a compounded product
- Personalized care team with ongoing dose check-ins
Hers cons
- No compounded/generic alternative offered
- Higher starting price than most compounded competitors
The reservation worth holding, particularly next to MedVi: there is no compounded tier to fall back on if the brand-name price stops working for you.
How MedVi works
MedVi provides compounded semaglutide starting at $179/month with a simple online intake, no clinic visits, and 24/7 certified medical support for weight loss. In this pairing, its distinguishing feature is a genuinely low promotional entry point with 24/7 clinical support behind it.
From signup to first shipment: simple online process, no clinic visits, then fast, free shipping. Billing follows a promotional first month, then standard rate structure.
Support: 24/7 support from certified medical professionals. The medications on offer are compounded semaglutide.
MedVi pros
- Three-month plan available at $649 (about $216/month) for patients who commit
- Simple online process with no clinic visits required
- 24/7 support from certified medical professionals
- Clinically dosed compounded semaglutide
MedVi cons
- Compounded medication only, no branded Ozempic or Wegovy
- No published outcome or weight loss guarantee
- Price increases sharply after the first month, $299 for a standalone month
The cost of choosing this over Hers: the price roughly doubles to $299 once the promotional month ends.
Who each program is actually built for
Choose Hers if:
- the monthly rate is the constraint — $149/mo against $299/mo
- you want an FDA-approved finished medication rather than a compounded preparation
- the twelve-month total is what you are optimizing ($1,788 against $3,468)
- what it leads on is worth paying for in your case: brand-name Wegovy at a price that usually buys compounded medication elsewhere
Choose MedVi if:
- you want to start on their timeline: simple online process, no clinic visits
- the level of clinical contact suits you: 24/7 support from certified medical professionals
- what it leads on is worth paying for in your case: a genuinely low promotional entry point with 24/7 clinical support behind it
- you are willing to commit for a term in exchange for a lower effective rate (3-month plan at $649)
The trade-offs, stated plainly
On price. $149/mo against $299/mo. MedVi is asking you to pay for a genuinely low promotional entry point with 24/7 clinical support behind it; decide whether that is a line item you will use.
On access. Hers advertises online intake with clinician review and home delivery, no insurance required; MedVi advertises simple online process, no clinic visits and fast, free shipping. Neither publishes its state coverage, so confirm you are eligible before paying for anything.
On predictability. The pricing structures differ (published rate per medication versus promotional first month, then standard rate), and structure, not headline rate, determines the twelve-month bill.
On clinical contact. Hers provides personalized care team with ongoing dose check-ins. MedVi provides 24/7 support from certified medical professionals. Both are asynchronous-first services and neither replaces a physician who can examine you.
What the evidence actually says
It is worth separating the program from the pharmacology. What follows is true of the medication regardless of which of these two writes the prescription.
Weight regain after withdrawal is the documented pattern: the STEP 1 extension recorded participants returning to close to their starting weight a year after stopping, per Diabetes, Obesity and Metabolism.
STEP 1 recorded a mean 14.9% reduction in body weight over 68 weeks on weekly semaglutide, against 2.4% for placebo, per NEJM, STEP 1.
Take the clinical questions to the prescribing clinician at whichever platform you choose; take the pricing questions to their support team before you pay.
Hers vs MedVi: common questions
Which is cheaper to start, Hers or MedVi?
Hers, at $149 against $179. Note that the cheapest first month and the cheapest year are often different providers here — check the 12-month row of the cost table before deciding on the entry price.
How fast can I start with Hers compared with MedVi?
Hers advertises online intake with clinician review, with home delivery, no insurance required. MedVi advertises simple online process, no clinic visits, with fast, free shipping. Both are subject to clinician review and to whether your state and health history clear, so treat the advertised timeline as a best case rather than a commitment.
Do Hers or MedVi take insurance?
Both run on a direct-pay basis: you pay the platform and it does not bill your insurer. Neither publishes HSA/FSA acceptance, so budget the full amount as out-of-pocket spending.
Is Hers or MedVi better for a first GLP-1 prescription?
First-timers usually get more from clinical access than from a lower rate, because the first two months are where most people stop. On that basis Hers has the stronger case; after month three, cost should take over.
What happens if I stop taking the medication?
Weight regain is the documented pattern, and it is not specific to either platform. Trial extension data has recorded participants regaining most of the weight they lost within a year of stopping semaglutide. Both Hers and MedVi price on a monthly basis, so treat the twelve-month figure as the realistic commitment rather than a first-month experiment.
Are Hers and MedVi legitimate?
Both are licensed telehealth platforms that route a prescription through a clinician review before anything is dispensed; neither sells medication without one. Hers operates on published rate per medication with pricing published upfront, MedVi on promotional first month, then standard rate, published upfront. The meaningful due diligence is on the medication category and the terms, not on whether the platforms are real.
The verdict
On the numbers, Hers wins the year: $1,788 against $2,592. That is the default answer, and it is the right one for anyone who mainly needs a reliable prescription and a shipment that arrives.
The case for MedVi is a genuinely low promotional entry point with 24/7 clinical support behind it. That is worth $67 a month to some patients and nothing at all to others — be honest about which you are.
The failure mode here is not picking the wrong platform; it is stopping treatment because the bill moved. Choose the one whose bill you can predict.
Keep comparing
- Hers vs TrimRxBrand-name vs compounded
- Shed vs HersPublished price vs quote-only
- MedVi vs JoinFridaysTirzepatide access
- MedVi vs altRxBudget vs premium
- Shed vs WellorithmBrand-name vs compounded
- Shed vs DirectmedsBrand-name vs compounded
See every provider in context on the weight loss rankings, or browse the full comparison index.
Disclaimers and methodology
Medical content is informational only and does not replace professional diagnosis, treatment, or emergency care.
Some links are affiliate links and may generate commission at no extra cost to you.
Pricing reflects what each provider published as of the sync date above and changes frequently; confirm the current rate, and the rate at your maintenance dose, before you pay. Six- and twelve-month totals are calculated from those published rates and exclude anything a provider bills separately.
eRxDoctor is an independent publisher. It is not a medical provider, is not affiliated with or endorsed by Hers or MedVi, and does not sell treatment. Read our ranking methodology.